Gyre Therapeutics Inc (GYRE)

In Q1 2026, Gyre Therapeutics reported a net loss of $9.9 million, with revenue of $22.5 million, leading to an 11.4% drop in shares. The company completed the acquisition of Cullgen Inc. for approximately $300 million. F351 received priority review status in China, and Gyre submitted an NDA for conditional approval. The CEO, Ying Luo, sold 10,136 shares. As of May 7, 2026, the stock price was $7.07, with a year-to-date decrease of 14.53% to 19.92%.

Demand for Gyre Therapeutics' products is influenced by the rising incidence of organ fibrosis, driven by factors such as aging demographics, obesity, diabetes, and chronic inflammatory conditions. ETUARY and Nintedanib utilization is linked to pulmonologist prescribing and NRDL placement. Avatrombopag demand is tied to oncology and hepatology practices. Hydronidone (F351) future demand will come from hepatology and metabolic clinics. There is no explicit information available to suggest a significant seasonal fluctuation in the demand for Gyre Therapeutics' products and services.

Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for organ fibrosis and inflammatory diseases. Their commercial-stage products include ETUARY (Pirfenidone) for idiopathic pulmonary fibrosis, Avatrombopag (Contiva®) for raising platelet counts, and Nintedanib (Etorel®) for fibrosing interstitial lung disease. The company's pipeline includes Hydronidone (F351) for MASH-associated liver fibrosis, F573 for acute/acute-on-chronic liver failure, F528 for chronic obstructive pulmonary disease, and F230 for pulmonary arterial hypertension. Gyre Therapeutics expanded its capabilities through the acquisition of Cullgen Inc., gaining access to targeted protein degradation platforms.

Gyre Therapeutics is headquartered in San Diego, California, with significant development and strategic activities in China. The company focuses on liver disease indications prevalent in Asian populations and leverages cross-border collaboration for clinical development and regulatory engagement across North America and Asia. Its subsidiary, Gyre Pharmaceuticals, operates in the PRC.

Gyre Therapeutics' brand reputation has been impacted by its listing on the "Cruelty Free Investing" list due to animal testing. The company has a consensus rating of "Hold" from analysts, with some downgrades. The acquisition of Cullgen Inc. was intended to strengthen Gyre's position as a multi-national biopharmaceutical company. The granting of priority review status for F351 in China reinforces the strength of its clinical data.

Approximately 23.99% of Gyre Therapeutics' stock is owned by institutional investors, including Vanguard Group Inc and BlackRock, Inc. GNI Group Ltd. is the largest individual shareholder, owning 72.47% of the company. Public companies collectively own 71% of Gyre Therapeutics stock. Retail investors hold a significant portion, with approximately 93.18% of the stock held by public companies and individual investors. Insiders own about 3.63% of the stock.